Pharmaceutical giant GSK has inked a deal with the University of Oxford that will see it pump tens of millions of pounds into research for cancer vaccines.
The FTSE 100 firm said under a collaboration with the university it would invest £50m over three years to find out whether cancers could be prevented from developing with jabs.
It said most cancers take years or decades to develop from normal cells and as a result drugs could be developed to recognise ‘precancerous’ ones and allow the immune system to eliminate them before they progress.
Tony Wood, GSK’s chief scientific officer, said: ‘We aim to generate key insights for people at risk of developing cancer.’
Investing for the future: Boss Emma Walmsley is pushing ahead with a strategy to boost GSK’s fortunes through lucrative cancer treatments and vaccines
The collaboration comes as boss Emma Walmsley pushes ahead with a strategy to boost GSK’s fortunes through lucrative cancer treatments and vaccines.
DIY INVESTING PLATFORMS
AJ Bell
AJ Bell
Easy investing and ready-made portfolios
Hargreaves Lansdown
Hargreaves Lansdown
Free fund dealing and investment ideas
interactive investor
interactive investor
Flat-fee investing from £4.99 per month
Saxo
Saxo
Get £200 back in trading fees
Trading 212
Trading 212
Free dealing and no account fee
Affiliate links: If you take out a product This is Money may earn a commission. These deals are chosen by our editorial team, as we think they are worth highlighting. This does not affect our editorial independence.
Compare the best investing account for you
